awmsg logo



eribulin (Halaven®)


Reference No. 979

Publication date:
30/09/2016


Appraisal information

eribulin (Halaven®) 0.44 mg/ml solution for injection


Company: Eisai Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 29/09/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, eribulin (Halaven®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.
Statement of Advice (SOA)
Download